Current knowledge on pancreatic cancer

Frontiers in Oncology

Volumn 2, Issue JAN, 2012, Pages

  Iovanna, Juan ^a   Mallmann, Maria Cecilia ^b   Gonçalves, Anthony ^c   Turrini, Olivier ^c   Dagorn, Jean Charles ^a  

^a INSERM   (France)

^b Centre d'Investigation Clinique   (France)

^c INSTITUT PAOLI CALMETTES   (France)

Author keywords

Cancer; Chemoprevention; Neoadjuvants; Oncogenes; Pancreas; Signaling; Suppressor genes; Surgery

Indexed keywords

AXITINIB; BEVACIZUMAB; CAPECITABINE; CHEMOKINE RECEPTOR CXCR4; CHOLECYSTOKININ RECEPTOR; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; ERLOTINIB; FOCAL ADHESION KINASE; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROSTAGLANDIN SYNTHASE; PROTEIN KINASE B; PROTEIN P53; SMAD2 PROTEIN; SMAD3 PROTEIN; SOMATOMEDIN C; SONIC HEDGEHOG PROTEIN; SORAFENIB; TELOMERASE; TERTOMOTIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; WNT PROTEIN;

ADJUVANT CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STEM CELL; CANCER SURVIVAL; CELL PROLIFERATION; DISEASE COURSE; DNA METHYLATION; DOWN REGULATION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HISTONE ACETYLATION; HUMAN; INFLAMMATION; ONCOGENE K RAS; ONCOGENE RAS; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL RATE; TUMOR INVASION; WNT SIGNALING PATHWAY;

EID: 84871209416     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2012.00006     Document Type: Review

References (222)

1. Abdelrahim, M., Newman, K., Vanderlaag, K., Samudio, I., and Safe, S. (2006). 3,3'-Diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5. Carcinogenesis 27, 717-728.
2. Abe, N., Watanabe, T., Masaki, T., Mori, T., Sugiyama, M., Uchimura, H., Fujioka, Y., Chiappetta, G., Fusco, A., and Atomi, Y. (2000). Pancreatic duct cell carcinomas express high levels of high mobility group I(Y) proteins. Cancer Res. 60, 3117-3122.
3. Abraham, S. C., Wu, T. T., Klimstra, D. S., Finn, L. S., Lee, J. H., Yeo, C. J., Cameron, J. L., and Hruban, R. H. (2001). Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposis-associated pancreatoblastomas: frequent alterations in the APC/β-catenin pathway and chromosome 11p. Am. J. Pathol. 159, 1619-1627.
4. Aird, I., Bentall, H. H., and Roberts, J. A. (1953). A relationship between cancer of stomach and the ABO blood groups. Br. Med. J. 1, 799-801.
5. Almoguera, C., Shibata, D., Forrester, K., Martin, J., Arnheim, N., and Perucho, M. (1988). Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53, 549-554.
6. Amundadottir, L., Kraft, P., Stolzenberg-Solomon, R. Z., Fuchs, C. S., Petersen, G. M., Arslan, A. A., Bueno-de-Mesquita, H. B., Gross, M., Helzlsouer, K., Jacobs, E. J., LaCroix, A., Zheng, W., Albanes, D., Bamlet, W., Berg, C. D., Berrino, F., Bingham, S., Buring, J. E., Bracci, P. M., Canzian, F., Clavel-Chapelon, F., Clipp, S., Cotterchio, M., de Andrade, M., Duell, E. J., Fox, J. W. Jr., Gallinger, S., Gaziano, J. M., Giovannucci, E. L., Goggins, M., González, C. A., Hallmans, G., Hankinson, S. E., Hassan, M., Holly, E. A., Hunter, D. J., Hutchinson, A., Jackson, R., Jacobs, K. B., Jenab, M., Kaaks, R., Klein, A. P., Kooperberg, C., Kurtz, R. C., Li, D., Lynch, S. M., Mandelson, M., McWilliams, R. R., Mendelsohn, J. B., Michaud, D. S., Olson, S. H., Overvad, K., Patel, A. V., Peeters, P. H., Rajkovic, A., Riboli, E., Risch, H. A., Shu, X. O., Thomas, G., Tobias, G. S., Trichopoulos, D., Van Den Eeden, S. K., Virtamo, J., Wactawski-Wende, J., Wolpin, B. M., Yu, H., Yu, K., Zeleniuch-Jacquotte, A., Chanock, S. J., Hartge, P., and Hoover, R. N. (2009). Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat. Genet. 41, 986-990.
7. Andea, A., Sarkar, F., and Adsay, V. N. (2003). Clinicopathological correlates of pancreatic intraepithelial neoplasia: a comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma. Mod. Pathol. 16, 996-1006.
8. Arrigo, A. P., Simon, S., Gibert, B., Kretz-Remy, C., Nivon, M., Czekalla, A., Guillet, D., Moulin, M., Diaz-Latoud, C., and Vicart, P. (2007). Hsp27 (HspB1) and αB-crystallin (HspB5) as therapeutic targets. FEBS Lett. 581, 3665-3674.
9. Asano, T., Yao, Y., Zhu, J., Li, D., Abbruzzese, J. L., and Reddy, S. A. (2004). The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-κB and c-Myc in pancreatic cancer cells. Oncogene 23, 8571-8580.
10. Baker, C. H., Trevino, J. G., Summy, J. M., Zhang, F., Caron, A., Nesbit, M., Gallick, G. E., and Fidler, I. J. (2006). Inhibition of PDGFR phosphorylation and Src and Akt activity by GN963 leads to therapy of human pancreatic cancer growing orthotopically in nude mice. Int. J. Oncol. 29, 125-138.
11. Banerjee, S., Zhang, Y., Ali, S., Bhuiyan, M., Wang, Z., Chiao, P. J., Philip, P. A., Abbruzzese, J., and Sarkar, F. H. (2005). Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res. 65, 9064-9072.
12. Banville, N., Geraghty, R., Fox, E., Leahy, D. T., Green, A., Keegan, D., Geoghegan, J., O'Donoghue, D., Hyland, J., and Sheahan, K. (2006). Medullary carcinoma of the pancreas in a man with hereditary nonpolyposis colorectal cancer due to a mutation of the MSH2 mismatch repair gene. Hum. Pathol. 37, 1498-1502.
13. Bardeesy, N., and DePinho, R. A. (2002). Pancreatic cancer biology and genetics. Nat. Rev. Cancer 2, 897-909.
14. Beltran, P. J., Mitchell, P., Chung, Y. A., Cajulis, E., Lu, J., Belmontes, B., Ho, J., Tsai, M. M., Zhu, M., Vonderfecht, S., Baserga, R., Kendall, R., Radinsky, R., and Calzone, F. J. (2009). AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol. Cancer Ther. 8, 1095-1105.
15. Berger, S. L. (2002). Histone modifications in transcriptional regulation. Curr. Opin. Genet. Dev. 12, 142-148.
16. Berlin, J. D., Catalano, P., Thomas, J. P., Kugler, J. W., Haller, D. G., and Benson, A. B. III. (2002). Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J. Clin. Oncol. 20, 3270-3275.
17. Berman, D. M., Karhadkar, S. S., Maitra, A., Montes De Oca, R., Gerstenblith, M. R., Briggs, K., Parker, A. R., Shimada, Y., Eshleman, J. R., Watkins, D. N., and Beachy, P. A. (2003). Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 425, 846-851.
18. Bernhardt, S. L., Gjertsen, M. K., Trachsel, S., Moller, M., Eriksen, J. A., Meo, M., Buanes, T., and Gaudernack, G. (2006). Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. Br. J. Cancer 95, 1474-1482.
19. Bhattacharyya, M., and Lemoine, N. R. (2006). Gene therapy developments for pancreatic cancer. Best Pract. Res. Clin. Gastroenterol. 20, 285-298.
20. Biliran, H. Jr., Wang, Y., Banerjee, S., Xu, H., Heng, H., Thakur, A., Bollig, A., Sarkar, F. H., and Liao, J. D. (2005). Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin. Cancer Res. 11, 6075-6086.
21. Bonafoux, D., and Lee, W. C. (2009). Strategies for TGF-β modulation: a review of recent patents. Expert Opin. Ther. Pat. 19, 1759-1769.
22. Bramhall, S. R., Rosemurgy, A., Brown, P. D., Bowry, C., and Buckels, J. A. (2001). Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J. Clin. Oncol. 19, 3447-3455.
23. Bramhall, S. R., Schulz, J., Nemunaitis, J., Brown, P. D., Baillet, M., and Buckels, J. A. (2002). A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br. J. Cancer 87, 161-167.
24. Brat, D. J., Lillemoe, K. D., Yeo, C. J., Warfield, P. B., and Hruban, R. H. (1998). Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. Am. J. Surg. Pathol. 22, 163-169.
25. Brockie, E., Anand, A., and Albores-Saavedra, J. (1998). Progression of atypical ductal hyperplasia/carcinoma in situ of the pancreas to invasive adenocarcinoma. Ann. Diagn. Pathol. 2, 286-292.
26. Bruserud, O., Stapnes, C., Ersvaer, E., Gjertsen, B. T., and Ryningen, A. (2007). Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell. Curr. Pharm. Biotechnol. 8, 388-400.
27. Buchler, P., Gazdhar, A., Schubert, M., Giese, N., Reber, H. A., Hines, O. J., Giese, T., Ceyhan, G. O., Muller, M., Buchler, M. W., and Friess, H. (2005). The Notch signaling pathway is related to neurovascular progression of pancreatic cancer. Ann. Surg. 242, 791-800; discussion 800-801.
28. Burris, H. A. III, Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., Nelson, R., Dorr, F. A., Stephens, C. D., and Von Hoff, D. D. (1997). Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15, 2403-2413.
29. Campbell, P. J., Yachida, S., Mudie, L. J., Stephens, P. J., Pleasance, E. D., Stebbings, L. A., Morsberger, L. A., Latimer, C., McLaren, S., Lin, M. L., McBride, D. J., Varela, I., Nik-Zainal, S. A., Leroy, C., Jia, M., Menzies, A., Butler, A. P., Teague, J. W., Griffin, C. A., Burton, J., Swerdlow, H., Quail, M. A., Stratton, M. R., Iacobuzio-Donahue, C., and Futreal, P. A. (2010). The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467, 1109-1113.
30. Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., and Zhang, Y. (2002). Role of histone H3 lysine 27 methylation in polycomb-group silencing. Science 298, 1039-1043.
31. Caplin, M., Savage, K., Khan, K., Brett, B., Rode, J., Varro, A., and Dhillon, A. (2000). Expression and processing of gastrin in pancreatic adenocarcinoma. Br. J. Surg. 87, 1035-1040.
32. Chau, I., Cunningham, D., Russell, C., Norman, A. R., Kurzawinski, T., Harper, P., Harrison, P., Middleton, G., Daniels, F., Hickish, T., Prendeville, J., Ross, P. J., Theis, B., Hull, R., Walker, M., Shankley, N., Kalindjian, B., Murray, G., Gillbanks, A., and Black, J. (2006). Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. Br. J. Cancer 94, 1107-1115.
33. Chauffert, B., Mornex, F., Bonnetain, F., Rougier, P., Mariette, C., Bouche, O., Bosset, J. F., Aparicio, T., Mineur, L., Azzedine, A., Hammel, P., Butel, J., Stremsdoerfer, N., Maingon, P., and Bedenne, L. (2008). Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann. Oncol. 19, 1592-1599.
34. Colucci, G., Giuliani, F., Gebbia, V., Biglietto, M., Rabitti, P., Uomo, G., Cigolari, S., Testa, A., Maiello, E., and Lopez, M. (2002). Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 94, 902-910.
35. Colucci, G., Labianca, R., Di Costanzo, F., Gebbia, V., Carteni, G., Massidda, B., Dapretto, E., Manzione, L., Piazza, E., Sannicolo, M., Ciaparrone, M., Cavanna, L., Giuliani, F., Maiello, E., Testa, A., Pederzoli, P., Falconi, M., Gallo, C., Di Maio, M., Perrone, F., Gruppo Oncologico Italia Meridionale (GOIM), Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD), and Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). (2010). Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J. Clin. Oncol. 28, 1645-1651.
36. Concannon, C. G., Gorman, A. M., and Samali, A. (2003). On the role of Hsp27 in regulating apoptosis. Apoptosis 8, 61-70.
37. Conroy, T., Desseigne, F., Ychou, M., Bouche, O., Guimbaud, R., Becouarn, Y., Adenis, A., Raoul, J. L., Gourgou-Bourgade, S., de la Fouchardiere, C., Bennouna, J., Bachet, J. B., Khemissa-Akouz, F., Péré-Vergé, D., Delbaldo, C., Assenat, E., Chauffert, B., Michel, P., Montoto-Grillot, C., Ducreux, M., Groupe Tumeurs Digestives of Unicancer, and PRODIGE Intergroup. (2011). FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817-1825.
38. Corcoran, R. B., Contino, G., Deshpande, V., Tzatsos, A., Conrad, C., Benes, C. H., Levy, D. E., Settleman, J., Engelman, J. A., and Bardeesy, N. (2011). STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res. 71, 5020-5029.
39. Coughlin, S. S., Calle, E. E., Patel, A. V., and Thun, M. J. (2000). Predictors of pancreatic cancer mortality among a large cohort of United States adults. Cancer Causes Control 11, 915-923.
40. Cowgill, S. M., and Muscarella, P. (2003). The genetics of pancreatic cancer. Am. J. Surg. 186, 279-286.
41. Cress, W. D., and Seto, E. (2000). Histone deacetylases, transcriptional control, and cancer. J. Cell. Physiol. 184, 1-16.
42. Cubilla, A. L., and Fitzgerald, P. J. (1976). Morphological lesions associated with human primary invasive nonendocrine pancreas cancer. Cancer Res. 36, 2690-2698.
43. Cunningham, D., Chau, I., Stocken, D. D., Valle, J. W., Smith, D., Steward, W., Harper, P. G., Dunn, J., Tudur-Smith, C., West, J., Falk, S., Crellin, A., Adab, F., Thompson, J., Leonard, P., Ostrowski, J., Eatock, M., Scheithauer, W., Herrmann, R., and Neoptolemos, J. P. (2009). Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 27, 5513-5518.
44. Dhillon, N., Aggarwal, B. B., Newman, R. A., Wolff, R. A., Kunnumakkara, A. B., Abbruzzese, J. L., Ng, C. S., Badmaev, V., and Kurzrock, R. (2008). Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res. 14, 4491-4499.
45. Diergaarde, B., Brand, R., Lamb, J., Cheong, S. Y., Stello, K., Barmada, M. M., Feingold, E., and Whitcomb, D. C. (2010). Pooling-based genome-wide association study implicates γ-glutamyltransferase 1 (GGT1) gene in pancreatic carcinogenesis. Pancreatology 10, 194-200.
46. Ding, X. Z., and Adrian, T. E. (2002). Resveratrol inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Pancreas 25, e71-e76.
47. Donadelli, M., Costanzo, C., Beghelli, S., Scupoli, M. T., Dandrea, M., Bonora, A., Piacentini, P., Budillon, A., Caraglia, M., Scarpa, A., and Palmieri, M. (2007). Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim. Biophys. Acta 1773, 1095-1106.
48. Dong, J. T., and Chen, C. (2009). Essential role of KLF5 transcription factor in cell proliferation and differentiation and its implications for human diseases. Cell. Mol. Life Sci. 66, 2691-2706.
49. Earl, J., Yan, L., Vitone, L. J., Risk, J., Kemp, S. J., McFaul, C., Neoptolemos, J. P., Greenhalf, W., European Registry of Hereditary Pancreatitis and Familial Pancreatic Cancer Kress, R., Sina-Frey, M., Hahn, S. A., Rieder, H., Bartsch, D. K., and German National Case Collection for Familial Pancreatic Cancer. (2006). Evaluation of the 4q32-34 locus in European familial pancreatic cancer. Cancer Epidemiol. Biomarkers Prev. 15, 1948-1955.
50. El-Rayes, B. F., Ali, S., Sarkar, F. H., and Philip, P. A. (2004). Cyclooxygenase-2-dependent and-independent effects of celecoxib in pancreatic cancer cell lines. Mol. Cancer Ther. 3, 1421-1426.
51. Esteller, M. (2008). Epigenetics in cancer. N. Engl. J. Med. 358, 1148-1159.
52. Fahy, B. N., Schlieman, M. G., Virudachalam, S., and Bold, R. J. (2004). Inhibition of AKT abrogates chemotherapy-induced NF-κB survival mechanisms: implications for therapy in pancreatic cancer. J. Am. Coll. Surg. 198, 591-599.
53. Fayard, E., Schoonjans, K., Annicotte, J. S., and Auwerx, J. (2003). Liver receptor homolog 1 controls the expression of carboxyl ester lipase. J. Biol. Chem. 278, 35725-35731.
54. Fearon, E. R., and Vogelstein, B. (1990). A genetic model for colorectal tumorigenesis. Cell 61, 759-767.
55. Feldmann, G., Dhara, S., Fendrich, V., Bedja, D., Beaty, R., Mullendore, M., Karikari, C., Alvarez, H., Iacobuzio-Donahue, C., Jimeno, A., Gabrielson, K. L., Matsui, W., and Maitra, A. (2007). Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res. 67, 2187-2196.
56. Fernandez-Zapico, M. E., Gonzalez-Paz, N. C., Weiss, E., Savoy, D. N., Molina, J. R., Fonseca, R., Smyrk, T. C., Chari, S. T., Urrutia, R., and Billadeau, D. D. (2005). Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. Cancer Cell 7, 39-49.
57. Friess, H., Langrehr, J. M., Oettle, H., Raedle, J., Niedergethmann, M., Dittrich, C., Hossfeld, D. K., Stoger, H., Neyns, B., Herzog, P., Piedbois, P., Dobrowolski, F., Scheithauer, W., Hawkins, R., Katz, F., Balcke, P., Vermorken, J., van Belle, S., Davidson, N., Esteve, A. A., Castellano, D., Kleeff, J., Tempia-Caliera, A. A., Kovar, A., and Nippgen, J. (2006). A randomized multi-center phase II trial of the angiogenesis inhibitor cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer 6, 285. doi:10.1186/1471-2407-6-285
58. Fujioka, S., Sclabas, G. M., Schmidt, C., Frederick, W. A., Dong, Q. G., Abbruzzese, J. L., Evans, D. B., Baker, C., and Chiao, P. J. (2003). Function of nuclear factor κB in pancreatic cancer metastasis. Clin. Cancer Res. 9, 346-354.
59. Funahashi, Y., Sugi, N. H., Semba, T., Yamamoto, Y., Hamaoka, S., Tsukahara-Tamai, N., Ozawa, Y., Tsuruoka, A., Nara, K., Takahashi, K., Okabe, T., Kamata, J., Owa, T., Ueda, N., Haneda, T., Yonaga, M., Yoshimatsu, K., and Wakabayashi, T. (2002). Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin a2 subunit on endothelium. Cancer Res. 62, 6116-6123.
60. Furukawa, T. (2007). Molecular genetics of intraductal papillary-mucinous neoplasms of the pancreas. J. Hepatobiliary Pancreat. Surg. 14, 233-237.
61. Furukawa, T., Duguid, W. P., Kobari, M., Matsuno, S., and Tsao, M. S. (1995). Hepatocyte growth factor and Met receptor expression in human pancreatic carcinogenesis. Am. J. Pathol. 147, 889-895.
62. Furuyama, K., Doi, R., Mori, T., Toyoda, E., Ito, D., Kami, K., Koizumi, M., Kida, A., Kawaguchi, Y., and Fujimoto, K. (2006). Clinical significance of focal adhesion kinase in resectable pancreatic cancer. World J. Surg. 30, 219-226.
63. Galmarini, C. M., Mackey, J. R., and Dumontet, C. (2002). Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol. 3, 415-424.
64. Garcea, G., Neal, C. P., Pattenden, C. J., Steward, W. P., and Berry, D. P. (2005). Molecular prognostic markers in pancreatic cancer: a systematic review. Eur. J. Cancer 41, 2213-2236.
65. Ghaneh, P., and Neoptolemos, J. P. (2004). Conclusions from the European Study Group for Pancreatic Cancer adjuvant trial of chemoradiotherapy and chemotherapy for pancreatic cancer. Surg. Oncol. Clin. N. Am. 13, 567-587.
66. Giardiello, F. M., Brensinger, J. D., Tersmette, A. C., Goodman, S. N., Petersen, G. M., Booker, S. V., Cruz-Correa, M., and Offerhaus, J. A. (2000). Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 119, 1447-1453.
67. Gillen, S., Schuster, T., Meyer Zum Buschenfelde, C., Friess, H., and Kleeff, J. (2010). Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 7, e1000267. doi: 10.1371/journal.pmed.1000267
68. Gjertsen, M. K., Buanes, T., Rosseland, A. R., Bakka, A., Gladhaug, I., Soreide, O., Eriksen, J. A., Moller, M., Baksaas, I., Lothe, R. A., Saeterdal, I., and Gaudernack, G. (2001). Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma. Int. J. Cancer 92, 441-450.
69. Glaser, K. B., Staver, M. J., Waring, J. F., Stender, J., Ulrich, R. G., and Davidsen, S. K. (2003). Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2, 151-163.
70. Goggins, M., Offerhaus, G. J., Hilgers, W., Griffin, C. A., Shekher, M., Tang, D., Sohn, T. A., Yeo, C. J., Kern, S. E., and Hruban, R. H. (1998a). Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am. J. Pathol. 152, 1501-1507.
71. Goggins, M., Shekher, M., Turnacioglu, K., Yeo, C. J., Hruban, R. H., and Kern, S. E. (1998b). Genetic alterations of the transforming growth factor β receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res. 58, 5329-5332.
72. Goldstein, A. M., Fraser, M. C., Struewing, J. P., Hussussian, C. J., Ranade, K., Zametkin, D. P., Fontaine, L. S., Organic, S. M., Dracopoli, N. C., Clark, W. H. Jr., and Tucker, M. A. (1995). Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N. Engl. J. Med. 333, 970-974.
73. Gonçalves, A., Viret, F., François, E., Dahan, L., Perrier, H., Lamy, R., Re, D., Largillier, R., Gasmi, M., Tchiknavorian, X., Turrini, O., Moureau-Zabotto, L., Delpero, J., and Viens, P. (2011). BAYPAN study: a double-blind, phase III randomized trial of gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with advanced pancreatic cancer. J. Clin. Oncol. 29(suppl.), abstr 4028.
74. Griffiths, E. A., and Gore, S. D. (2008). DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin. Hematol. 45, 23-30.
75. Guerra, C., Collado, M., Navas, C., Schuhmacher, A. J., Hernandez-Porras, I., Canamero, M., Rodriguez-Justo, M., Serrano, M., and Barbacid, M. (2011). Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell 19, 728-739.
76. Guerra, C., Schuhmacher, A. J., Canamero, M., Grippo, P. J., Verdaguer, L., Perez-Gallego, L., Dubus, P., Sandgren, E. P., and Barbacid, M. (2007). Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11, 291-302.
77. Habbe, N., Koorstra, J. B., Mendell, J. T., Offerhaus, G. J., Ryu, J. K., Feldmann, G., Mullendore, M. E., Goggins, M. G., Hong, S. M., and Maitra, A. (2009). MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol. Ther. 8, 340-346.
78. Hakam, A., Fang, Q., Karl, R., and Coppola, D. (2003). Coexpression of IGF-1R and c-Src proteins in human pancreatic ductal adenocarcinoma. Dig. Dis. Sci. 48, 1972-1978.
79. Heinemann, V., Boeck, S., Hinke, A., Labianca, R., and Louvet, C. (2008). Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 8, 82. doi:10.1186/1471-2407-8-82
80. Heinemann, V., Quietzsch, D., Gieseler, F., Gonnermann, M., Schonekas, H., Rost, A., Neuhaus, H., Haag, C., Clemens, M., Heinrich, B., Vehling-Kaiser, U., Fuchs, M., Fleckenstein, D., Gesierich, W., Uthgenannt, D., Einsele, H., Holstege, A., Hinke, A., Schalhorn, A., and Wilkowski, R. (2006). Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J. Clin. Oncol. 24, 3946-3952.
81. Heinrich, S., Pestalozzi, B. C., Schafer, M., Weber, A., Bauerfeind, P., Knuth, A., and Clavien, P. A. (2008). Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. J. Clin. Oncol. 26, 2526-2531.
82. Hermann, P. C., Huber, S. L., Herrler, T., Aicher, A., Ellwart, J. W., Guba, M., Bruns, C. J., and Heeschen, C. (2007). Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1, 313-323.
83. Herrmann, R., Bodoky, G., Ruhstaller, T., Glimelius, B., Bajetta, E., Schuller, J., Saletti, P., Bauer, J., Figer, A., Pestalozzi, B., Köhne, C. H., Mingrone, W., Stemmer, S. M., Tàmas, K., Kornek, G. V., Koeberle, D., Cina, S., Bernhard, J., Dietrich, D., Scheithauer, W., Swiss Group for Clinical Cancer Research, and Central European Cooperative Oncology Group. (2007). Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J. Clin. Oncol. 25, 2212-2217.
84. Hildmann, C., Riester, D., and Schwienhorst, A. (2007). Histone deacetylases-an important class of cellular regulators with a variety of functions. Appl. Microbiol. Biotechnol. 75, 487-497.
85. Hiyama, E., Kodama, T., Shinbara, K., Iwao, T., Itoh, M., Hiyama, K., Shay, J. W., Matsuura, Y., and Yokoyama, T. (1997). Telomerase activity is detected in pancreatic cancer but not in benign tumors. Cancer Res. 57, 326-331.
86. Hruban, R. H., Adsay, N. V., Albores-Saavedra, J., Compton, C., Garrett, E. S., Goodman, S. N., Kern, S. E., Klimstra, D. S., Kloppel, G., Longnecker, D. S., Lüttges, J., and Offerhaus, G. J. (2001). Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am. J. Surg. Pathol. 25, 579-586.
87. Hruban, R. H., Goggins, M., Parsons, J., and Kern, S. E. (2000). Progression model for pancreatic cancer. Clin. Cancer Res. 6, 2969-2972.
88. Hruban, R. H., Takaori, K., Klimstra, D. S., Adsay, N. V., Albores-Saavedra, J., Biankin, A. V., Biankin, S. A., Compton, C., Fukushima, N., Furukawa, T., Goggins, M., Kato, Y., Klöppel, G., Longnecker, D. S., Lüttges, J., Maitra, A., Offerhaus, G. J., Shimizu, M., and Yonezawa, S. (2004). An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am. J. Surg. Pathol. 28, 977-987.
89. Hu, W. G., Liu, T., Xiong, J. X., and Wang, C. Y. (2007). Blockade of sonic hedgehog signal pathway enhances antiproliferative effect of EGFR inhibitor in pancreatic cancer cells. Acta Pharmacol. Sin. 28, 1224-1230.
90. Hussain, S. P., Hofseth, L. J., and Harris, C. C. (2003). Radical causes of cancer. Nat. Rev. Cancer 3, 276-285.
91. Ischenko, I., Guba, M., Yezhelyev, M., Papyan, A., Schmid, G., Green, T., Fennell, M., Jauch, K. W., and Bruns, C. J. (2007). Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer. Angiogenesis 10, 167-182.
92. Itzkowitz, S. H., Yuan, M., Ferrell, L. D., Ratcliffe, R. M., Chung, Y. S., Satake, K., Umeyama, K., Jones, R. T., and Kim, Y. S. (1987). Cancer-associated alterations of blood group antigen expression in the human pancreas. J. Natl. Cancer Inst. 79, 425-434.
93. Jang, M., Cai, L., Udeani, G. O., Slowing, K. V., Thomas, C. F., Beecher, C. W., Fong, H. H., Farnsworth, N. R., Kinghorn, A. D., Mehta, R. G., Moon, R. C., and Pezzuto, J. M. (1997). Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275, 218-220.
94. Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C., and Thun, M. J. (2006). Cancer statistics, 2006. CA Cancer J. Clin. 56, 106-130.
95. Jiang, J., Lee, E. J., Gusev, Y., and Schmittgen, T. D. (2005). Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res. 33, 5394-5403.
96. Jimeno, A., Rubio-Viqueira, B., Amador, M. L., Grunwald, V., Maitra, A., Iacobuzio-Donahue, C., and Hidalgo, M. (2007). Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer. Mol. Cancer Ther. 6, 1079-1088.
97. Jin, H., Yang, R., Zheng, Z., Romero, M., Ross, J., Bou-Reslan, H., Carano, R. A., Kasman, I., Mai, E., Young, J., Zha, J., Zhang, Z., Ross, S., Schwall, R., Colbern, G., and Merchant, M. (2008). MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res. 68, 4360-4368.
98. Jones, S., Zhang, X., Parsons, D. W., Lin, J. C., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., Hong, S. M., Fu, B., Lin, M. T., Calhoun, E. S., Kamiyama, M., Walter, K., Nikolskaya, T., Nikolsky, Y., Hartigan, J., Smith, D. R., Hidalgo, M., Leach, S. D., Klein, A. P., Jaffee, E. M., Goggins, M., Maitra, A., Iacobuzio-Donahue, C., Eshleman, J. R., Kern, S. E., Hruban, R. H., Karchin, R., Papadopoulos, N., Parmigiani, G., Vogelstein, B., Velculescu, V. E., and Kinzler, K. W. (2008). Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806.
99. Karin, M. (2006). Nuclear factor-κB in cancer development and progression. Nature 441, 431-436.
100. Kawasaki, D., Emori, Y., Eta, R., Iino, Y., Hamano, H., Yoshinaga, K., Tanaka, T., Takei, M., and Watson, S. A. (2008). Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro. Cancer Chemother. Pharmacol. 61, 883-892.
101. Khan, N., Afaq, F., Saleem, M., Ahmad, N., and Mukhtar, H. (2006). Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res. 66, 2500-2505.
102. Kindler, H. L., Niedzwiecki, D., Hollis, D., Sutherland, S., Schrag, D., Hurwitz, H., Innocenti, F., Mulcahy, M. F., O'Reilly, E., Wozniak, T. F., Picus, J., Bhargava, P., Mayer, R. J., Schilsky, R. L., and Goldberg, R. M. (2010). Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J. Clin. Oncol. 28, 3617-3622.
103. Kornmann, M., Arber, N., and Korc, M. (1998). Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. J. Clin. Invest. 101, 344-352.
104. Kotake, Y., Cao, R., Viatour, P., Sage, J., Zhang, Y., and Xiong, Y. (2007). pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4α tumor suppressor gene. Genes Dev. 21, 49-54.
105. Lee, C. J., Dosch, J., and Simeone, D. M. (2008). Pancreatic cancer stem cells. J. Clin. Oncol. 26, 2806-2812.
106. Lee, E. J., Gusev, Y., Jiang, J., Nuovo, G. J., Lerner, M. R., Frankel, W. L., Morgan, D. L., Postier, R. G., Brackett, D. J., and Schmittgen, T. D. (2007). Expression profiling identifies microRNA signature in pancreatic cancer. Int. J. Cancer 120, 1046-1054.
107. Levy, L., and Hill, C. S. (2005). Smad4 dependency defines two classes of transforming growth factor β (TGF-β) target genes and distinguishes TGF-β-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. Mol. Cell. Biol. 25, 8108-8125.
108. Li, L., Aggarwal, B. B., Shishodia, S., Abbruzzese, J., and Kurzrock, R. (2004a). Nuclear factor-κB and IκB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 101, 2351-2362.
109. Li, Y., Ellis, K. L., Ali, S., El-Rayes, B. F., Nedeljkovic-Kurepa, A., Kucuk, O., Philip, P. A., and Sarkar, F. H. (2004b). Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-κB in BxPC-3 pancreatic cancer cell line. Pancreas 28, e90-e95.
110. Li, Y., Ahmed, F., Ali, S., Philip, P. A., Kucuk, O., and Sarkar, F. H. (2005). Inactivation of nuclear factor κB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res. 65, 6934-6942.
111. Li, Y., Bhuiyan, M., Vaitkevicius, V. K., and Sarkar, F. H. (1998). Molecular analysis of the p53 gene in pancreatic adenocarcinoma. Diagn. Mol. Pathol. 7, 4-9.
112. Li, Y., Kucuk, O., Hussain, M., Abrams, J., Cher, M. L., and Sarkar, F. H. (2006). Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-κB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. Cancer Res. 66, 4816-4825.
113. Lian, J. P., Word, B., Taylor, S., Hammons, G. J., and Lyn-Cook, B. D. (2004). Modulation of the constitutive activated STAT3 transcription factor in pancreatic cancer prevention: effects of indole-3-carbinol (I3C) and genistein. Anticancer Res. 24, 133-137.
114. Liau, S. S., Ashley, S. W., and Whang, E. E. (2006). Lentivirus-mediated RNA interference of HMGA1 promotes chemosensitivity to gemcitabine in pancreatic adenocarcinoma. J. Gastrointest. Surg. 10, 1254-1262; discussion 1263.
115. Liau, S. S., and Whang, E. (2008). HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma. Clin. Cancer Res. 14, 1470-1477.
116. Liptay, S., Weber, C. K., Ludwig, L., Wagner, M., Adler, G., and Schmid, R. M. (2003). Mitogenic and antiapoptotic role of constitutive NF-κB/Rel activity in pancreatic cancer. Int. J. Cancer 105, 735-746.
117. Liu, W., Bloom, D. A., Cance, W. G., Kurenova, E. V., Golubovskaya, V. M., and Hochwald, S. N. (2008). FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. Carcinogenesis 29, 1096-1107.
118. Liu, T. J., LaFortune, T., Honda, T., Ohmori, O., Hatakeyama, S., Meyer, T., Jackson, D., de Groot, J., and Yung, W. K. (2007). Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol. Cancer Ther. 6, 1357-1367.
119. Loakes, D. (2001). Survey and summary: the applications of universal DNA base analogues. Nucleic Acids Res. 29, 2437-2447.
120. Lomberk, G., Wallrath, L., and Urrutia, R. (2006). The heterochromatin protein 1 family. Genome Biol. 7, 228.
121. Longnecker, D. S., Adsay, N. V., Fernandez-del Castillo, C., Hruban, R. H., Kasugai, T., Klimstra, D. S., Kloppel, G., Luttges, J., Memoli, V. A., Tosteson, T. D., Yanagisawa, A., Wilentz, R., and Zamboni, G. (2005). Histopathological diagnosis of pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms: interobserver agreement. Pancreas 31, 344-349.
122. Louvet, C., Labianca, R., Hammel, P., Lledo, G., Zampino, M. G., Andre, T., Zaniboni, A., Ducreux, M., Aitini, E., Taieb, J., Faroux, R., Lepere, C., de Gramont, A., GERCOR, and GISCAD. (2005). Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J. Clin. Oncol. 23, 3509-3516.
123. Low, S. K., Kuchiba, A., Zembutsu, H., Saito, A., Takahashi, A., Kubo, M., Daigo, Y., Kamatani, N., Chiku, S., Totsuka, H., Ohnami, S., Hirose, H., Shimada, K., Okusaka, T., Yoshida, T., Nakamura, Y., and Sakamoto, H. (2010). Genome-wide association study of pancreatic cancer in Japanese population. PLoS ONE 5, e11824. doi:10.1371/journal.pone.0011824
124. Lowenfels, A. B., Maisonneuve, P., Cavallini, G., Ammann, R. W., Lankisch, P. G., Andersen, J. R., Dimagno, E. P., Andren-Sandberg, A., and Domellof, L. (1993). Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N. Engl. J. Med. 328, 1433-1437.
125. Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., Downing, J. R., Jacks, T., Horvitz, H. R., and Golub, T. R. (2005). MicroRNA expression profiles classify human cancers. Nature 435, 834-838.
126. Manolio, T. A. (2010). Genomewide association studies and assessment of the risk of disease. N. Engl. J. Med. 363, 166-176.
127. Marcus, D. M. (1969). The ABO and Lewis blood-group system. Immunochemistry, genetics and relation to human disease. N. Engl. J. Med. 280, 994-1006.
128. Martin, N. E., Brunner, T. B., Kiel, K. D., DeLaney, T. F., Regine, W. F., Mohiuddin, M., Rosato, E. F., Haller, D. G., Stevenson, J. P., Smith, D., Pramanik, B., Tepper, J., Tanaka, W. K., Morrison, B., Deutsch, P., Gupta, A. K., Muschel, R. J., McKenna, W. G., Bernhard, E. J., and Hahn, S. M. (2004). A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer. Clin. Cancer Res. 10, 5447-5454.
129. McClintock, B. (1941). The stability of broken ends of chromosomes in Zea mays. Genetics 26, 234-282.
130. Milella, M., Gelibter, A., Di Cosimo, S., Bria, E., Ruggeri, E. M., Carlini, P., Malaguti, P., Pellicciotta, M., Terzoli, E., and Cognetti, F. (2004). Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer 101, 133-138.
131. Mimeault, M., Brand, R. E., Sasson, A. A., and Batra, S. K. (2005). Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies. Pancreas 31, 301-316.
132. Miyamoto, Y., Maitra, A., Ghosh, B., Zechner, U., Argani, P., Iacobuzio-Donahue, C. A., Sriuranpong, V., Iso, T., Meszoely, I. M., Wolfe, M. S., Hruban, R. H., Ball, D. W., Schmid, R. M., and Leach, S. D. (2003). Notch mediates TGF α-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 3, 565-576.
133. Mohammad, R. M., Banerjee, S., Li, Y., Aboukameel, A., Kucuk, O., and Sarkar, F. H. (2006). Cisplatin-induced antitumor activity is potentiated by the soy isoflavone genistein in BxPC-3 pancreatic tumor xenografts. Cancer 106, 1260-1268.
134. Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., Campos, D., Lim, R., Ding, K., Clark, G., Voskoglou-Nomikos, T., Ptasynski, M., Parulekar, W., and National Cancer Institute of Canada Clinical Trials Group. (2007). Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25, 1960-1966.
135. Moore, M. J., Hamm, J., Dancey, J., Eisenberg, P. D., Dagenais, M., Fields, A., Hagan, K., Greenberg, B., Colwell, B., Zee, B., Tu, D., Ottaway, J., Humphrey, R., Seymour, L., National Cancer Institute of Canada Clinical Trials Group. (2003). Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 21, 3296-3302.
136. Mori-Iwamoto, S., Kuramitsu, Y., Ryozawa, S., Mikuria, K., Fujimoto, M., Maehara, S., Maehara, Y., Okita, K., Nakamura, K., and Sakaida, I. (2007). Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine. Int. J. Oncol. 31, 1345-1350.
137. Mori-Iwamoto, S., Taba, K., Kuramitsu, Y., Ryozawa, S., Tanaka, T., Maehara, S., Maehara, Y., Okita, K., Nakamura, K., and Sakaida, I. (2009). Interferon-γ down-regulates heat shock protein 27 of pancreatic cancer cells and helps in the cytotoxic effect of gemcitabine. Pancreas 38, 224-226.
138. Morton, J. P., Karim, S. A., Graham, K., Timpson, P., Jamieson, N., Athineos, D., Doyle, B., McKay, C., Heung, M. Y., Oien, K. A., Frame, M. C., Evans, T. R., Sansom, O. J., and Brunton, V. G. (2010). Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 139, 292-303.
139. Muerkoster, S., Arlt, A., Witt, M., Gehrz, A., Haye, S., March, C., Grohmann, F., Wegehenkel, K., Kalthoff, H., Folsch, U. R., and Schafer, H. (2003). Usage of the NF-κB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer. Int. J. Cancer 104, 469-476.
140. Mukhtar, H., and Ahmad, N. (1999). Green tea in chemoprevention of cancer. Toxicol. Sci. 52, 111-117.
141. Mund, C., Brueckner, B., and Lyko, F. (2006). Reactivation of epigenetically silenced genes by DNA methyltransferase inhibitors: basic concepts and clinical applications. Epigenetics 1, 7-13.
142. Munshi, N., Jeay, S., Li, Y., Chen, C. R., France, D. S., Ashwell, M. A., Hill, J., Moussa, M. M., Leggett, D. S., and Li, C. J. (2010). ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol. Cancer Ther. 9, 1544-1553.
143. Nakamura, Y., Migita, T., Hosoda, F., Okada, N., Gotoh, M., Arai, Y., Fukushima, M., Ohki, M., Miyata, S., Takeuchi, K., Imoto, I., Katai, H., Yamaguchi, T., Inazawa, J., Hirohashi, S., Ishikawa, Y., and Shibata, T. (2009). Kruppel-like factor 12 plays a significant role in poorly differentiated gastric cancer progression. Int. J. Cancer 125, 1859-1867.
144. Nakashima, H., Nakamura, M., Yamaguchi, H., Yamanaka, N., Akiyoshi, T., Koga, K., Yamaguchi, K., Tsuneyoshi, M., Tanaka, M., and Katano, M. (2006). Nuclear factor-κB contributes to hedgehog signaling pathway activation through sonic hedgehog induction in pancreatic cancer. Cancer Res. 66, 7041-7049.
145. Nawroth, R., van Zante, A., Cervantes, S., McManus, M., Hebrok, M., and Rosen, S. D. (2007). Extracellular sulfatases, elements of the Wnt signaling pathway, positively regulate growth and tumorigenicity of human pancreatic cancer cells. PLoS ONE 2, e392. doi:10.1371/journal.pone.0000392
146. Neoptolemos, J. P., Stocken, D. D., Tudur Smith, C., Bassi, C., Ghaneh, P., Owen, E., Moore, M., Padbury, R., Doi, R., Smith, D., and Buchler, M. W. (2009). Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and-3(v1) trials. Br. J. Cancer 100, 246-250.
147. Nkondjock, A., Ghadirian, P., Johnson, K. C., and Krewski, D. (2005). Dietary intake of lycopene is associated with reduced pancreatic cancer risk. J. Nutr. 135, 592-597.
148. Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J., Ridwelski, K., Schramm, H., Fahlke, J., Zuelke, C., Burkart, C., Gutberlet, K., Kettner, E., Schmalenberg, H., Weigang-Koehler, K., Bechstein, W. O., Niedergethmann, M., Schmidt-Wolf, I., Roll, L., Doerken, B., and Riess, H. (2007). Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297, 267-277.
149. Ogura, Y., Mizumoto, K., Nagai, E., Murakami, M., Inadome, N., Saimura, M., Matsumoto, K., Nakamura, T., Maemondo, M., Nukiwa, T., and Tanaka, M. (2006). Peritumoral injection of adenovirus vector expressing NK4 combined with gemcitabine treatment suppresses growth and metastasis of human pancreatic cancer cells implanted orthotopically in nude mice and prolongs survival. Cancer Gene Ther. 13, 520-529.
150. Okami, J., Yamamoto, H., Fujiwara, Y., Tsujie, M., Kondo, M., Noura, S., Oshima, S., Nagano, H., Dono, K., Umeshita, K., Ishikawa, O., Sakon, M., Matsuura, N., Nakamori, S., and Monden, M. (1999). Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin. Cancer Res. 5, 2018-2024.
151. Olson, P., Lu, J., Zhang, H., Shai, A., Chun, M. G., Wang, Y., Libutti, S. K., Nakakura, E. K., Golub, T. R., and Hanahan, D. (2009). MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev. 23, 2152-2165.
152. Ouaïssi, M., Sielezneff, I., Silvestre, R., Sastre, B., Bernard, J. P., Lafontaine, J. S., Payan, M. J., Dahan, L., Pirrò, N., Seitz, J. F., Mas, E., Lombardo, D., and Ouaissi, A. (2008). High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas. Ann. Surg. Oncol. 15, 2318-2328.
153. Ougolkov, A. V., Bilim, V. N., and Billadeau, D. D. (2008). Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clin. Cancer Res. 14, 6790-6796.
154. Palmer, D. H., Stocken, D. D., Hewitt, H., Markham, C. E., Hassan, A. B., Johnson, P. J., Buckels, J. A., and Bramhall, S. R. (2007). A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann. Surg. Oncol. 14, 2088-2096.
155. Pan, L. N., Lu, J., and Huang, B. (2007). HDAC inhibitors: a potential new category of anti-tumor agents. Cell. Mol. Immunol. 4, 337-343.
156. Pasca di Magliano, M., Biankin, A. V., Heiser, P. W., Cano, D. A., Gutierrez, P. J., Deramaudt, T., Segara, D., Dawson, A. C., Kench, J. G., Henshall, S. M., Sutherland, R. L., Dlugosz, A., Rustgi, A. K., and Hebrok, M. (2007). Common activation of canonical Wnt signaling in pancreatic adenocarcinoma. PLoS ONE 2, e1155. doi:10.1371/journal.pone.0001155
157. Petersen, G. M., Amundadottir, L., Fuchs, C. S., Kraft, P., Stolzenberg-Solomon, R. Z., Jacobs, K. B., Arslan, A. A., Bueno-de-Mesquita, H. B., Gallinger, S., Gross, M., Helzlsouer, K., Holly, E. A., Jacobs, E. J., Klein, A. P., LaCroix, A., Li, D., Mandelson, M. T., Olson, S. H., Risch, H. A., Zheng, W., Albanes, D., Bamlet, W. R., Berg, C. D., Boutron-Ruault, M. C., Buring, J. E., Bracci, P. M., Canzian, F., Clipp, S., Cotterchio, M., de Andrade, M., Duell, E. J., Gaziano, J. M., Giovannucci, E. L., Goggins, M., Hallmans, G., Hankinson, S. E., Hassan, M., Howard, B., Hunter, D. J., Hutchinson, A., Jenab, M., Kaaks, R., Kooperberg, C., Krogh, V., Kurtz, R. C., Lynch, S. M., McWilliams, R. R., Mendelsohn, J. B., Michaud, D. S., Parikh, H., Patel, A. V., Peeters, P. H., Rajkovic, A., Riboli, E., Rodriguez, L., Seminara, D., Shu, X. O., Thomas, G., Tjønneland, A., Tobias, G. S., Trichopoulos, D., Van Den Eeden, S. K., Virtamo, J., Wactawski-Wende, J., Wang, Z., Wolpin, B. M., Yu, H., Yu, K., Zeleniuch-Jacquotte, A., Fraumeni, J. F. Jr., Hoover, R. N., Hartge, P., and Chanock, S. J. (2010). A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat. Genet. 42, 224-228.
158. Petersen, G. M., de Andrade, M., Goggins, M., Hruban, R. H., Bondy, M., Korczak, J. F., Gallinger, S., Lynch, H. T., Syngal, S., Rabe, K. G., Seminara, D., and Klein, A. P. (2006). Pancreatic cancer genetic epidemiology consortium. Cancer Epidemiol. Biomarkers Prev. 15, 704-710.
159. Philip, P. A., Benedetti, J., Corless, C. L., Wong, R., O'Reilly, E. M., Flynn, P. J., Rowland, K. M., Atkins, J. N., Mirtsching, B. C., Rivkin, S. E., Khorana, A. A., Goldman, B., Fenoglio-Preiser, C. M., Abbruzzese, J. L., and Blanke, C. D. (2010). Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J. Clin. Oncol. 28, 3605-3610.
160. Piao, W., Wang, Y., Adachi, Y., Yamamoto, H., Li, R., Imsumran, A., Li, H., Maehata, T., Ii, M., Arimura, Y., Lee, C. T., Shinomura, Y., Carbone, D. P., and Imai, K. (2008). Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas. Mol. Cancer Ther. 7, 1483-1493.
161. Pogue-Geile, K. L., Chen, R., Bronner, M. P., Crnogorac-Jurcevic, T., Moyes, K. W., Dowen, S., Otey, C. A., Crispin, D. A., George, R. D., Whitcomb, D. C., and Brentnall, T. A. (2006). Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. PLoS Med. 3, e516. doi:10.1371/journal.pmed.0030516
162. Poplin, E., Feng, Y., Berlin, J., Rothenberg, M. L., Hochster, H., Mitchell, E., Alberts, S., O'Dwyer, P., Haller, D., Catalano, P., Cella, D., and Benson, A. B. III. (2009). Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 27, 3778-3785.
163. Qanungo, S., Das, M., Haldar, S., and Basu, A. (2005). Epigallocatechin-3-gallate induces mitochondrial membrane depolarization and caspase-dependent apoptosis in pancreatic cancer cells. Carcinogenesis 26, 958-967.
164. Ricart, A. D., Tolcher, A. W., Liu, G., Holen, K., Schwartz, G., Albertini, M., Weiss, G., Yazji, S., Ng, C., and Wilding, G. (2008). Volociximab, a chimeric monoclonal antibody that specifically binds α5β1 integrin: a phase I, pharmacokinetic, and biological correlative study. Clin. Cancer Res. 14, 7924-7929.
165. Rinehart, J., Adjei, A. A., Lorusso, P. M., Waterhouse, D., Hecht, J. R., Natale, R. B., Hamid, O., Varterasian, M., Asbury, P., Kaldjian, E. P., Gulyas, S., Mitchell, D. Y., Herrera, R., Sebolt-Leopold, J. S., and Meyer, M. B. (2004). Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J. Clin. Oncol. 22, 4456-4462.
166. Ringrose, L. (2007). Polycomb comes of age: genome-wide profiling of target sites. Curr. Opin. Cell Biol. 19, 290-297.
167. Rocchi, P., Beraldi, E., Ettinger, S., Fazli, L., Vessella, R. L., Nelson, C., and Gleave, M. (2005). Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res. 65, 11083-11093.
168. Rocchi, P., So, A., Kojima, S., Signaevsky, M., Beraldi, E., Fazli, L., Hurtado-Coll, A., Yamanaka, K., and Gleave, M. (2004). Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res. 64, 6595-6602.
169. Roldo, C., Missiaglia, E., Hagan, J. P., Falconi, M., Capelli, P., Bersani, S., Calin, G. A., Volinia, S., Liu, C. G., Scarpa, A., and Croce, C. M. (2006). MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J. Clin. Oncol. 24, 4677-4684.
170. Romero, D., Iglesias, M., Vary, C. P., and Quintanilla, M. (2008). Functional blockade of Smad4 leads to a decrease in β-catenin levels and signaling activity in human pancreatic carcinoma cells. Carcinogenesis 29, 1070-1076.
171. Ruggeri, B. A., Huang, L., Wood, M., Cheng, J. Q., and Testa, J. R. (1998). Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol. Carcinog. 21, 81-86.
172. Sato, N., Fukushima, N., Maitra, A., Matsubayashi, H., Yeo, C. J., Cameron, J. L., Hruban, R. H., and Goggins, M. (2003). Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res. 63, 3735-3742.
173. Schlieman, M. G., Fahy, B. N., Ramsamooj, R., Beckett, L., and Bold, R. J. (2003). Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br. J. Cancer 89, 2110-2115.
174. Schmitz-Winnenthal, F. H., Z'Graggen, K., Volk, C., Schmied, B. M., and Buchler, M. W. (2003). Intraductal papillary mucinous tumors of the pancreas. Curr. Gastroenterol. Rep. 5, 133-140.
175. Schutte, M., Hruban, R. H., Geradts, J., Maynard, R., Hilgers, W., Rabindran, S. K., Moskaluk, C. A., Hahn, S. A., Schwarte-Waldhoff, I., Schmiegel, W., Baylin, S. B., Kern, S. E., and Herman, J. G. (1997). Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res. 57, 3126-3130.
176. Schwartz, A. M., and Henson, D. E. (2007). Familial and sporadic pancreatic carcinoma, epidemiologic concordance. Am. J. Surg. Pathol. 31, 645-646.
177. Seo, Y., Baba, H., Fukuda, T., Takashima, M., and Sugimachi, K. (2000). High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 88, 2239-2245.
178. Shafaee, Z., Schmidt, H., Du, W., Posner, M., and Weichselbaum, R. (2006). Cyclopamine increases the cytotoxic effects of paclitaxel and radiation but not cisplatin and gemcitabine in Hedgehog expressing pancreatic cancer cells. Cancer Chemother. Pharmacol. 58, 765-770.
179. Shen, Y. M., Yang, X. C., Yang, C., and Shen, J. K. (2008). Enhanced therapeutic effects for human pancreatic cancer by application K-ras and IGF-IR antisense oligodeoxynucleotides. World J. Gastroenterol. 14, 5176-5185.
180. Singh, E. K., Ravula, S., Pan, C. M., Pan, P. S., Vasko, R. C., Lapera, S. A., Weerasinghe, S. V., Pflum, M. K., and McAlpine, S. R. (2008). Synthesis and biological evaluation of histone deacetylase inhibitors that are based on FR235222: a cyclic tetrapeptide scaffold. Bioorg. Med. Chem. Lett. 18, 2549-2554.
181. Singh, M., and Maitra, A. (2007). Precursor lesions of pancreatic cancer: molecular pathology and clinical implications. Pancreatology 7, 9-19.
182. Sohn, T. A., Yeo, C. J., Cameron, J. L., Iacobuzio-Donahue, C. A., Hruban, R. H., and Lillemoe, K. D. (2001). Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathologic entity. Ann. Surg. 234, 313-321; discussion 321-312.
183. Sood, P., Krek, A., Zavolan, M., Macino, G., and Rajewsky, N. (2006). Cell-type-specific signatures of microRNAs on target mRNA expression. Proc. Natl. Acad. Sci. U.S.A. 103, 2746-2751.
184. Spano, J. P., Chodkiewicz, C., Maurel, J., Wong, R., Wasan, H., Barone, C., Letourneau, R., Bajetta, E., Pithavala, Y., Bycott, P., Trask, P., Liau, K., Ricart, A. D., Kim, S., and Rixe, O. (2008). Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 371, 2101-2108.
185. Su, G. H., Hruban, R. H., Bansal, R. K., Bova, G. S., Tang, D. J., Shekher, M. C., Westerman, A. M., Entius, M. M., Goggins, M., Yeo, C. J., and Kern, S. E. (1999). Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am. J. Pathol. 154, 1835-1840.
186. Szafranska, A. E., Davison, T. S., John, J., Cannon, T., Sipos, B., Maghnouj, A., Labourier, E., and Hahn, S. A. (2007). MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 26, 4442-4452.
187. Takayama, Y., Kokuryo, T., Yokoyama, Y., Nagino, M., Nimura, Y., Senga, T., and Hamaguchi, M. (2008). MEK inhibitor enhances the inhibitory effect of imatinib on pancreatic cancer cell growth. Cancer Lett. 264, 241-249.
188. Talar-Wojnarowska, R., and Malecka-Panas, E. (2006). Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications. Med. Sci. Monit. 12, RA186-RA193.
189. Thayer, S. P., di Magliano, M. P., Heiser, P. W., Nielsen, C. M., Roberts, D. J., Lauwers, G. Y., Qi, Y. P., Gysin, S., Fernandez-del Castillo, C., Yajnik, V., Antoniu, B., McMahon, M., Warshaw, A. L., and Hebrok, M. (2003). Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 425, 851-856.
190. Tomioka, D., Maehara, N., Kuba, K., Mizumoto, K., Tanaka, M., Matsumoto, K., and Nakamura, T. (2001). Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model. Cancer Res. 61, 7518-7524.
191. Toubaji, A., Achtar, M., Provenzano, M., Herrin, V. E., Behrens, R., Hamilton, M., Bernstein, S., Venzon, D., Gause, B., Marincola, F., and Khleif, S. N. (2008). Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers. Cancer Immunol. Immunother. 57, 1413-1420.
192. Trapasso, F., Sarti, M., Cesari, R., Yendamuri, S., Dumon, K. R., Aqeilan, R. I., Pentimalli, F., Infante, L., Alder, H., Abe, N., Watanabe, T., Viglietto, G., Croce, C. M., and Fusco, A. (2004). Therapy of human pancreatic carcinoma based on suppression of HMGA1 protein synthesis in preclinical models. Cancer Gene Ther. 11, 633-641.
193. Trevino, J. G., Summy, J. M., Lesslie, D. P., Parikh, N. U., Hong, D. S., Lee, F. Y., Donato, N. J., Abbruzzese, J. L., Baker, C. H., and Gallick, G. E. (2006). Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am. J. Pathol. 168, 962-972.
194. Tsuda, N., Ishiyama, S., Li, Y., Ioannides, C. G., Abbruzzese, J. L., and Chang, D. Z. (2006). Synthetic microRNA designed to target glioma-associated antigen 1 transcription factor inhibits division and induces late apoptosis in pancreatic tumor cells. Clin. Cancer Res. 12, 6557-6564.
195. Van Cutsem, E., van de Velde, H., Karasek, P., Oettle, H., Vervenne, W. L., Szawlowski, A., Schoffski, P., Post, S., Verslype, C., Neumann, H., Safran, H., Humblet, Y., Perez Ruixo, J., Ma, Y., and Von Hoff, D. (2004). Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol. 22, 1430-1438.
196. Van Cutsem, E., Vervenne, W. L., Bennouna, J., Humblet, Y., Gill, S., Van Laethem, J. L., Verslype, C., Scheithauer, W., Shang, A., Cosaert, J., and Moore, M. J. (2009). Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J. Clin. Oncol. 27, 2231-2237.
197. Vernejoul, F., Ghenassia, L., Souque, A., Lulka, H., Drocourt, D., Cordelier, P., Pradayrol, L., Pyronnet, S., Buscail, L., and Tiraby, G. (2006). Gene therapy based on gemcitabine chemosensitization suppresses pancreatic tumor growth. Mol. Ther. 14, 758-767.
198. Vire, E., Brenner, C., Deplus, R., Blanchon, L., Fraga, M., Didelot, C., Morey, L., Van Eynde, A., Bernard, D., Vanderwinden, J. M., Bollen, M., Esteller, M., Di Croce, L., de Launoit, Y., and Fuks, F. (2006). The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439, 871-874.
199. Volinia, S., Calin, G. A., Liu, C. G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., Prueitt, R. L., Yanaihara, N., Lanza, G., Scarpa, A., Vecchione, A., Negrini, M., Harris, C. C., and Croce, C. M. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U.S.A. 103, 2257-2261.
200. Wan, J., Xia, Y., Liu, Y., Wang, M., Rocchi, P., Yao, J., Qu, F., Neyts, J., Iovanna, J. L., and Peng, L. (2009). Discovery of novel arylethynyltriazole ribonucleosides with selective and effective antiviral and antiproliferative activity. J. Med. Chem. 52, 1144-1155.
201. Wang, W., Abbruzzese, J. L., Evans, D. B., and Chiao, P. J. (1999). Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. Oncogene 18, 4554-4563.
202. Wang, W., Chen, S., Brune, K. A., Hruban, R. H., Parmigiani, G., and Klein, A. P. (2007). PancPRO: risk assessment for individuals with a family history of pancreatic cancer. J. Clin. Oncol. 25, 1417-1422.
203. Wang, Z., Banerjee, S., Li, Y., Rahman, K. M., Zhang, Y., and Sarkar, F. H. (2006a). Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-κB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res. 66, 2778-2784.
204. Wang, Z., Sengupta, R., Banerjee, S., Li, Y., Zhang, Y., Rahman, K. M., Aboukameel, A., Mohammad, R., Majumdar, A. P., Abbruzzese, J. L., and Sarkar, F. H. (2006b). Epidermal growth factor receptor-related protein inhibits cell growth and invasion in pancreatic cancer. Cancer Res. 66, 7653-7660.
205. Wang, Z., Zhang, Y., Banerjee, S., Li, Y., and Sarkar, F. H. (2006c). Inhibition of nuclear factor κB activity by genistein is mediated via Notch-1 signaling pathway in pancreatic cancer cells. Int. J. Cancer 118, 1930-1936.
206. Wang, Z., Zhang, Y., Banerjee, S., Li, Y., and Sarkar, F. H. (2006d). Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer 106, 2503-2513.
207. Wang, Z., Zhang, Y., Li, Y., Banerjee, S., Liao, J., and Sarkar, F. H. (2006e). Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol. Cancer Ther. 5, 483-493.
208. Wang, Z., Ma, Q., Liu, Q., Yu, H., Zhao, L., Shen, S., and Yao, J. (2008). Blockade of SDF-1/CXCR4 signalling inhibits pancreatic cancer progression in vitro via inactivation of canonical Wnt pathway. Br. J. Cancer 99, 1695-1703.
209. Watanabe, S., Ueda, Y., Akaboshi, S., Hino, Y., Sekita, Y., and Nakao, M. (2009). HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells. Am. J. Pathol. 174, 854-868.
210. Wei, D., Wang, L., He, Y., Xiong, H. Q., Abbruzzese, J. L., and Xie, K. (2004). Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res. 64, 2030-2038.
211. Wei, Y., Xia, W., Zhang, Z., Liu, J., Wang, H., Adsay, N. V., Albarracin, C., Yu, D., Abbruzzese, J. L., Mills, G. B., Bast, R. C. Jr., Hortobagyi, G. N., and Hung, M. C. (2008). Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol. Carcinog. 47, 701-706.
212. Whitcomb, D. C., Gorry, M. C., Preston, R. A., Furey, W., Sossenheimer, M. J., Ulrich, C. D., Martin, S. P., Gates, L. K. Jr., Amann, S. T., Toskes, P. P., Liddle, R., McGrath, K., Uomo, G., Post, J. C., and Ehrlich, G. D. (1996). Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat. Genet. 14, 141-145.
213. Wilentz, R. E., Goggins, M., Redston, M., Marcus, V. A., Adsay, N. V., Sohn, T. A., Kadkol, S. S., Yeo, C. J., Choti, M., Zahurak, M., Johnson, K., Tascilar, M., Offerhaus, G. J., Hruban, R. H., and Kern, S. E. (2000). Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: a newly described and characterized entity. Am. J. Pathol. 156, 1641-1651.
214. Winter, J. M., Cameron, J. L., Lillemoe, K. D., Campbell, K. A., Chang, D., Riall, T. S., Coleman, J., Sauter, P. K., Canto, M., Hruban, R. H., Schulick, R. D., Choti, M. A., and Yeo, C. J. (2006). Periampullary and pancreatic incidentaloma: a single institution's experience with an increasingly common diagnosis. Ann. Surg. 243, 673-680; discussion 680-673.
215. Wolpin, B. M., Hezel, A. F., Abrams, T., Blaszkowsky, L. S., Meyerhardt, J. A., Chan, J. A., Enzinger, P. C., Allen, B., Clark, J. W., Ryan, D. P., and Fuchs, C. S. (2009). Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J. Clin. Oncol. 27, 193-198.
216. Xia, Y., Liu, Y., Wan, J., Wang, M., Rocchi, P., Qu, F., Iovanna, J. L., and Peng, L. (2009). Novel triazole ribonucleoside down-regulates heat shock protein 27 and induces potent anticancer activity on drug-resistant pancreatic cancer. J. Med. Chem. 52, 6083-6096.
217. Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., Velculescu, V. E., Kinzler, K. W., Vogelstein, B., and Iacobuzio-Donahue, C. A. (2010). Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114-1117.
218. Yamamoto, H., Itoh, F., Nakamura, H., Fukushima, H., Sasaki, S., Perucho, M., and Imai, K. (2001). Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability. Cancer Res. 61, 3139-3144.
219. Zeng, G., Germinaro, M., Micsenyi, A., Monga, N. K., Bell, A., Sood, A., Malhotra, V., Sood, N., Midda, V., Monga, D. K., Kokkinakis, D. M., and Monga, S. P. (2006). Aberrant Wnt/β-catenin signaling in pancreatic adenocarcinoma. Neoplasia 8, 279-289.
220. Zhang, H., Morisaki, T., Nakahara, C., Matsunaga, H., Sato, N., Nagumo, F., Tadano, J., and Katano, M. (2003). PSK-mediated NF-κB inhibition augments docetaxel-induced apoptosis in human pancreatic cancer cells NOR-P1. Oncogene 22, 2088-2096.
221. Zhang, Y., Banerjee, S., Wang, Z., Xu, H., Zhang, L., Mohammad, R., Aboukameel, A., Adsay, N. V., Che, M., Abbruzzese, J. L., Majumdar, A. P., and Sarkar, F. H. (2006). Antitumor activity of epidermal growth factor receptor-related protein is mediated by inactivation of ErbB receptors and nuclear factor-κB in pancreatic cancer. Cancer Res. 66, 1025-1032.
222. Zhang, Y., Banerjee, S., Wang, Z. W., Marciniak, D. J., Majumdar, A. P., and Sarkar, F. H. (2005). Epidermal growth factor receptor-related protein inhibits cell growth and induces apoptosis of BxPC3 pancreatic cancer cells. Cancer Res. 65, 3877-3882.